Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Immunicum's nomination committee for the Annual General Meeting 2017 appointed

Immunicum AB
Posted on: 22 Nov 16

In accordance with the resolution by the Annual General Meeting of Immunicum on 26 October 2016, the Chairman of the Board of Directors has convened a Nomination Committee for the Annual General Meeting 2017. The four largest shareholders who wish to participate in the nomination committe are entitled to appoint one member each. In addition, the chairman of the board of directors participates in the nomination committee.

The members of the nomination committee are:

Evert Carlsson, appointed by Swedbank Robur Fonder AB
Martin Lindström, appointed by Loggen Invest AB
Bengt Andersson, appointed by Bengt Andersson
Mats Dahlgren, appointed by Mats Dahlgren
Agneta Edberg, Chairman of the Board of Directors

In connection with the statutory meeting, Evert Carlsson has been appointed chairman of the nomination committee.

The Annual General Meeting will be held on Wednesday 26 April 2017.

Information about the work of the Nomination Committe can be found at Immunicum's website . Shareholders wishing to make proposals to the Nomination Committee should submit their proposal in writing via e-mail to .

For further information, please contact:

Evert Carlsson, Chairman of the nomination committee

Agneta Edberg, Chairman of the board of directors
Phone: +46 (0) 70 555 75 18

Certified Adviser is Redeye AB.
Phone: +46 (0) 8 545 013 31

About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the company's most advanced product - INTUVAX® against kidney cancer - was started in May 2015. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier. .

The information in this press release is disclosed pursuant to the Nasdaq First North's Rulebook. The information was released for public disclosure through the agency of the company's contact person on 22 November 2016 at 08:30 CET.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via GlobeNewswire

Last updated on: 23/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.